| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 1,234 | 1,961 | 1,728 | 1,573 | 1,501 | 1,539 | 1,449 | 1,463 | 1,485 | 1,453 | 1,467 | 1,508 | 1,708 | 1,861 | 1,868 | 1,951 | 1,839 | 1,996 | 2,002 | 1,977 | 1,927 | 2,018 | 1,991 | 1,980 | 1,954 | 2,160 | 2,154 | 2,142 | 2,160 | 2,322 | 2,277 | 2,449 | 2,461 | 2,582 | 2,654 | 2,746 | 2,726 | 2,839 | 2,815 | 2,795 | 2,891 |
| Expenses | 992 | 1,035 | 976 | 1,118 | 1,016 | 1,114 | 1,099 | 1,127 | 1,139 | 1,077 | 1,088 | 1,104 | 1,344 | 1,395 | 1,421 | 1,490 | 1,740 | 1,481 | 1,464 | 1,426 | 1,398 | 1,395 | 1,382 | 1,388 | 1,355 | 1,457 | 1,477 | 1,570 | 2,055 | 1,635 | 1,612 | 1,767 | 1,764 | 1,800 | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 2,019 |
| EBITDA | 242 | 926 | 752 | 455 | 485 | 425 | 350 | 336 | 346 | 376 | 379 | 404 | 364 | 466 | 447 | 461 | 99 | 515 | 538 | 551 | 529 | 623 | 609 | 592 | 599 | 703 | 677 | 572 | 105 | 687 | 665 | 682 | 697 | 782 | 819 | 883 | 864 | 884 | 865 | 900 | 872 |
| Operating Profit % | 13 % | 45 % | 41 % | 26 % | 31 % | 26 % | 22 % | 20 % | 18 % | 20 % | 22 % | 23 % | 19 % | 24 % | 24 % | 24 % | 5 % | 25 % | 26 % | 26 % | 27 % | 31 % | 30 % | 30 % | 29 % | 31 % | 30 % | 25 % | 2 % | 29 % | 29 % | 28 % | 28 % | 29 % | 30 % | 31 % | 31 % | 31 % | 31 % | 31 % | 31 % |
| Depreciation | 60 | 57 | 59 | 59 | 63 | 68 | 69 | 73 | 97 | 80 | 84 | 94 | 151 | 150 | 152 | 156 | 160 | 160 | 163 | 163 | 168 | 161 | 165 | 167 | 165 | 165 | 168 | 167 | 162 | 155 | 163 | 193 | 196 | 191 | 201 | 213 | 203 | 197 | 198 | 199 | 201 |
| Interest | 47 | 55 | 48 | 43 | 38 | 49 | 51 | 48 | 58 | 56 | 51 | 80 | 121 | 122 | 126 | 133 | 123 | 122 | 116 | 111 | 102 | 102 | 92 | 91 | 73 | 68 | 71 | 62 | 57 | 55 | 69 | 102 | 107 | 103 | 91 | 80 | 80 | 75 | 64 | 57 | 56 |
| Profit Before Tax | 155 | 875 | 681 | 377 | 410 | 346 | 253 | 245 | 244 | 266 | 272 | 259 | 134 | 232 | 205 | 275 | -150 | 279 | 296 | 319 | 293 | 402 | 384 | 357 | 383 | 484 | 472 | 357 | -87 | 532 | 463 | 419 | 433 | 531 | 559 | 631 | 631 | 656 | 661 | 691 | 665 |
| Tax | 25 | 225 | 172 | 87 | 126 | 54 | 46 | 16 | 38 | 78 | 68 | 201 | -94 | 69 | 26 | 29 | 2 | 63 | 52 | 68 | -21 | 81 | 74 | 60 | 59 | 154 | 156 | 108 | 31 | 178 | 151 | 127 | 146 | 153 | 173 | 188 | 182 | 199 | 208 | 188 | 167 |
| Net Profit | 130 | 650 | 509 | 290 | 284 | 292 | 207 | 229 | 206 | 188 | 204 | 58 | 228 | 163 | 179 | 246 | -152 | 216 | 244 | 251 | 314 | 321 | 310 | 297 | 324 | 330 | 316 | 249 | -118 | 354 | 312 | 292 | 287 | 378 | 386 | 443 | 449 | 457 | 453 | 503 | 498 |
| EPS in ₹ | 7.70 | 38.40 | 30.01 | 17.19 | 16.82 | 17.28 | 12.25 | 13.47 | 12.17 | 11.08 | 12.07 | 3.37 | 13.55 | 9.66 | 10.57 | 14.50 | -8.95 | 12.74 | 14.48 | 14.77 | 18.56 | 18.98 | 18.32 | 17.52 | 19.16 | 19.53 | 18.63 | 14.75 | -6.97 | 20.90 | 9.22 | 8.63 | 8.48 | 11.18 | 11.39 | 13.10 | 13.27 | 13.51 | 13.37 | 14.88 | 14.71 |
Torrent Pharmaceuticals
Torrent Pharmaceuticals
3,603.80
+83.90
(2.38%)
Market Cap
1,19,129.40 Cr
EPS
56.47
PE Ratio
62.12
Dividend Yield
0.17 %
Industry
Healthcare52 Week High
3,590.70
52 Week Low
2,886.45
PB Ratio
15.68
Debt to Equity
0.50
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from27 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,699.00 | #1 4,05,967.50 | 35.44 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 54.94 | |
6,616.50 | 1,75,700.40 | 80.22 | 9,712.00 | 0.89 | 2,191 | 23.05 | 42.61 | |
1,532.50 | 1,20,178.80 | 23.35 | 28,409.50 | 7.12 | 5,291 | 9.88 | 63.13 | |
3,603.80 | #4 1,19,129.40 | #9 62.12 | #8 11,539.40 | #7 11.59 | #9 1,911 | #4 10.91 | 71.36 | |
2,603.40 | 1,06,876.10 | 61.51 | 12,744.20 | 19.57 | 2,007 | -10.91 | 60.17 | |
1,277.90 | 1,05,615.00 | #1 18.58 | 33,741.20 | 16.73 | 5,725 | 1.26 | 51.48 | |
976.40 | 97,730.50 | 21.02 | 23,511.00 | 13.82 | 4,615 | -0.19 | 53.23 | |
1,951.00 | 88,662.90 | 27.33 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 51.88 | |
33,780.00 | 73,480.10 | 52.02 | 6,684.70 | 10.80 | 1,414 | 27.83 | 50.65 | |
1,122.80 | 64,707.10 | 18.71 | 31,378.10 | 17.55 | 3,366 | -0.50 | 45.80 |
Forecast
Actual
Growth Rate
Revenue Growth
11.59 %
Net Income Growth
33.02 %
Cash Flow Change
-20.85 %
ROE
20.26 %
ROCE
23.16 %
EBITDA Margin (Avg.)
6.33 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 |
| Fixed Assets | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,122 | 8,138 | 7,947 |
| Current Assets | 4,051 | 4,688 | 4,880 | 5,262 | 5,038 | 4,979 | 5,522 | 5,165 | 5,314 | 5,612 | 5,623 |
| Capital Work in Progress | 678 | 1,042 | 520 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 |
| Other Assets | 4,095 | 4,378 | 4,691 | 5,249 | 5,403 | 5,763 | 5,940 | 5,821 | 5,926 | 6,389 | 6,409 |
| Total Liabilities | 7,904 | 9,058 | 9,702 | 14,243 | 14,121 | 14,010 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 |
| Current Liabilities | 2,824 | 3,286 | 2,738 | 5,202 | 5,165 | 5,454 | 4,892 | 4,415 | 5,447 | 5,425 | 4,717 |
| Non Current Liabilities | 2,589 | 2,278 | 2,613 | 4,418 | 4,231 | 3,732 | 3,346 | 2,732 | 3,367 | 2,779 | 2,682 |
| Total Equity | 2,491 | 3,495 | 4,351 | 4,623 | 4,724 | 4,823 | 5,837 | 5,953 | 6,198 | 6,856 | 7,591 |
| Reserve & Surplus | 2,406 | 3,410 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,422 |
| Share Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -90 | 438 | 18 | -366 | 238 | 73 | -89 | -174 | 110 | 327 | -262 |
| Investing Activities | -2,113 | -870 | -798 | -4,677 | -246 | 229 | -444 | -196 | -2,335 | -160 | -549 |
| Operating Activities | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 |
| Financing Activities | 1,212 | -1,435 | -193 | 3,417 | -1,314 | -1,549 | -1,651 | -1,781 | 77 | -2,780 | -2,298 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Jul 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 71.25 % | 68.31 % | 68.31 % | 68.31 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.14 % | 14.22 % | 14.46 % | 16.17 % | 16.31 % | 16.09 % |
| DIIs | 6.53 % | 6.71 % | 6.76 % | 6.78 % | 7.52 % | 7.82 % | 7.76 % | 8.89 % | 8.87 % | 9.00 % | 8.31 % | 7.16 % | 6.44 % | 7.26 % | 7.27 % | 7.08 % | 8.35 % | 8.35 % | 8.65 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.89 % | 7.72 % | 7.58 % | 7.29 % | 7.25 % | 7.10 % | 7.13 % | 4.59 % | 4.73 % | 4.47 % | 4.38 % | 4.25 % | 4.15 % | 4.09 % | 3.98 % | 4.34 % | 4.61 % | 4.51 % | 4.44 % |
| Others | 14.33 % | 14.33 % | 14.42 % | 14.68 % | 13.98 % | 13.83 % | 13.86 % | 15.27 % | 15.16 % | 15.28 % | 16.07 % | 17.34 % | 18.16 % | 3.27 % | 3.28 % | 2.87 % | 2.56 % | 2.52 % | 2.50 % |
| No of Share Holders | 0 | 72,616 | 64,525 | 64,309 | 67,205 | 63,229 | 62,933 | 64,557 | 67,866 | 63,831 | 61,572 | 69,612 | 69,117 | 71,154 | 74,765 | 79,848 | 85,035 | 86,005 | 81,856 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 14 | 14 | 17 | 32 | 35 | 48 | 22 | 28 | 32 |
| Dividend Yield (%) | 0.00 | 2.24 | 1.44 | 1.72 | 2.51 | 2.51 | 3.12 | 0.85 | 0.87 | 0.91 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jul 2025 |  Quarterly Result Announcement | NA | 28 Jul 2025 | 3,521.85 | 3,515.90 |
| 28 Jul 2025 |  Annual General Meeting | NA | 28 Jul 2025 | 3,334.10 | 3,515.90 |
| 20 Jun 2025 |  Dividend | ₹ 6.00 /share | 20 Jun 2025 | 3,302.80 | 3,164.00 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 3,237.70 | 3,302.80 |
| 01 Feb 2025 | Dividend | ₹ 26.00 /share | 31 Jan 2025 | 3,266.20 | 3,259.20 |
| 24 Jan 2025 | Quarterly Result Announcement | NA | 24 Jan 2025 | 3,274.45 | 3,266.20 |
| 25 Oct 2024 | Quarterly Result Announcement | NA | 25 Oct 2024 | 3,557.25 | 3,317.25 |
| 23 Jul 2024 | Annual General Meeting | NA | 23 Jul 2024 | 2,840.45 | 3,028.80 |
| 21 Jun 2024 | Dividend | ₹ 6.00 /share | 21 Jun 2024 | 2,691.80 | 2,858.10 |
| 12 Feb 2024 | Dividend | ₹ 22.00 /share | 12 Feb 2024 | 2,512.50 | 2,657.35 |
| 23 Jun 2023 | Dividend | ₹ 8.00 /share | 23 Jun 2023 | 1,705.95 | 1,862.65 |
| 03 Feb 2023 | Dividend | ₹ 14.00 /share | 03 Feb 2023 | 1,584.65 | 1,541.05 |
| 11 Jul 2022 |  Bonus | 1:1 | 08 Jul 2022 | 1,441.88 | 1,466.70 |
| 06 Jun 2022 | Dividend | ₹ 15.00 /share | 03 Jun 2022 | 1,296.25 | 1,390.33 |
| 06 Jun 2022 | Dividend | ₹ 8.00 /share | 03 Jun 2022 | 1,296.25 | 1,390.33 |
| 03 Feb 2022 | Dividend | ₹ 25.00 /share | 02 Feb 2022 | 1,552.43 | 1,367.98 |
| 18 Jun 2021 | Dividend | ₹ 15.00 /share | 17 Jun 2021 | 1,382.38 | 1,476.95 |
| 16 Feb 2021 | Dividend | ₹ 20.00 /share | 15 Feb 2021 | 1,376.03 | 1,303.15 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4 days ago
4 days agoBoard Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 20154 days ago
4 days agoDisclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) Letter To Shareholders - Integrated Annual Report FY 2024-25Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 05, 2025
Jul 05, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Jul 04, 2025Reg. 34 (1) Annual Report.Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 01, 2025
Jul 01, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 29, 2025
Jun 29, 2025Board Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (Listing Regulations).Jun 29, 2025
Jun 29, 2025Redemption Of Commercial Paper Issued Under ISIN INE685A14120Jun 27, 2025
Jun 27, 2025Intimation Regarding Issue Of Commercial PapersJun 26, 2025
Jun 26, 2025Redemption Of Commercial Paper Issued Under ISIN INE685A14138Jun 23, 2025
Jun 23, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesJun 20, 2025
Jun 20, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 23, 2025
May 23, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 20, 2025
May 20, 2025Intimation Of Record Date For The Purpose Of Payment Of Final Dividend For FY 2024-25May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Raising of FundsMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Date of payment of DividendMay 20, 2025
May 20, 2025Corporate Action-Board approves DividendMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Dated 20-May-25May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Results Q4 And Year Ended 31-03-2025.May 20, 2025
May 20, 2025Results Q4 And Year Ended 31-03-2025.May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Board Meeting Intimation for To Consider And Approve The Audited Financial Results Of The Company For The Year Ended On 31-Mar-25May 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-CessationMay 11, 2025
May 11, 2025Closure of Trading WindowMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesMar 26, 2025
Mar 26, 2025Redemption Of Commercial Paper Issued Under ISIN INE685A14112Mar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 19, 2025
Mar 19, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 21, 2025
Feb 21, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 17, 2025
Feb 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 08, 2025
Feb 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Feb 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Technical Indicators
RSI(14)
Neutral 65.81
ATR(14)
Less Volatile 68.30
STOCH(9,6)
Overbought 86.87
STOCH RSI(14)
Overbought 83.82
MACD(12,26)
Bullish 13.38
ADX(14)
Strong Trend 33.76
UO(9)
Bearish 61.25
ROC(12)
Uptrend And Accelerating 5.00
WillR(14)
Overbought -19.03
Mutual Fund Holdings
HDFC Large Cap Fund Direct-Growth 
SBI Mid Cap Direct Plan-Growth 
UTI Nifty200 Momentum 30 Index Fund Direct - Growth 
Axis ELSS Tax Saver Direct Plan-Growth 
Edelweiss Balanced Advantage Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Franklin India Large Cap Fund Direct-Growth 
Aditya Birla Sun Life Quant Fund Direct-Growth 
ICICI Prudential Innovation Fund Direct - Growth 
Nippon India Multi Asset Allocation Fund Direct - Growth 
Motilal Oswal Nifty 200 Momentum 30 Index Fund Direct - Growth 
Mirae Asset Healthcare Fund Direct - Growth 
Canara Robeco Multi Asset Allocation Fund Direct-Growth 
Bandhan Large Cap Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company with a global presence. It specializes in cardiovascular, central nervous system, vitamins and nutrients, gastro-intestinal, and anti-diabetes therapies. The company operates through wholly-owned subsidiaries in over 40 countries, with major operations in the US, Germany, and Brazil. Torrent Pharmaceuticals has manufacturing facilities in multiple Indian states and an R&D center in Ahmedabad. Founded in 1959, the company has grown through acquisitions, expansions, and product launches. It has entered various therapeutic segments including dermatology, gynecology, and oncology. Torrent Pharmaceuticals is engaged in research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations both domestically and internationally.
Chairperson NameSamir Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
